Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations-Reference-Cited by-同舟云学术

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations

Published:2014-11 Issue:11 Volume:21 Page:1857-1865
ISSN:0967-5868
Container-title:Journal of Clinical Neuroscience
language:en
Short-container-title:Journal of Clinical Neuroscience

Author:

Broadley Simon A.,Barnett Michael H.,Boggild Mike,Brew Bruce J.,Butzkueven Helmut,Heard Robert,Hodgkinson Suzanne,Kermode Allan G.,Lechner-Scott Jeannette,Macdonell Richard A.L.,Marriott Mark,Mason Deborah F.,Parratt John,Reddel Stephen W.,Shaw Cameron P.,Slee Mark,Spies Judith,Taylor Bruce V.,Carroll William M.,Kilpatrick Trevor J.,King John,McCombe Pamela A.,Pollard John D.,Willoughby Ernest

Publisher

Elsevier BV

Subject

Physiology (medical),Clinical Neurology,Neurology,General Medicine,Surgery

Reference122 articles.

1. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon;Bosca;Mult Scler,2008

2. Scoring treatment response in patients with relapsing multiple sclerosis;Sormani;Mult Scler,2013

3. Predicting responders to therapies for multiple sclerosis;Rio;Nat Rev Neurol,2009

4. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients;Rio;Mult Scler,2008

5. Freedom from disease activity in multiple sclerosis;Havrdova;Neurology,2010

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine;Pharmaceutics;2024-02-07

2. Disease-modifying therapies do not affect sleep quality or daytime sleepiness in a large Australian MS cohort;Multiple Sclerosis and Related Disorders;2023-10

3. Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns;Pharmaceutics;2023-04-05

4. Individual Differences in the Patient Experience of Relapsing Multiple Sclerosis (RMS): A Multi-Country Qualitative Exploration of Drivers of Treatment Preferences Among People Living with RMS;The Patient - Patient-Centered Outcomes Research;2023-04-05

5. Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis;Journal of Neurology, Neurosurgery & Psychiatry;2022-07-28